424 related articles for article (PubMed ID: 24682267)
21. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.
Wang X; Björklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B
PLoS One; 2010 Nov; 5(11):e14085. PubMed ID: 21124928
[TBL] [Abstract][Full Text] [Related]
22. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1.
Zukerberg LR; Benedict WF; Arnold A; Dyson N; Harlow E; Harris NL
Blood; 1996 Jul; 88(1):268-76. PubMed ID: 8704183
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation.
László T; Nagy M; Kelényi G; Matolcsy A
Leuk Res; 2000 Jan; 24(1):27-31. PubMed ID: 10634642
[TBL] [Abstract][Full Text] [Related]
25. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma.
M'kacher R; Bennaceur A; Farace F; Laugé A; Plassa LF; Wittmer E; Dossou J; Violot D; Deutsch E; Bourhis J; Stoppa-Lyonnet D; Ribrag V; Carde P; Parmentier C; Bernheim A; Turhan AG
Oncogene; 2003 Sep; 22(39):7905-12. PubMed ID: 12970738
[TBL] [Abstract][Full Text] [Related]
26. Nonimmunoglobulin gene hypermutation in germinal center B cells.
Peng HZ; Du MQ; Koulis A; Aiello A; Dogan A; Pan LX; Isaacson PG
Blood; 1999 Apr; 93(7):2167-72. PubMed ID: 10090923
[TBL] [Abstract][Full Text] [Related]
27. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
28. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
Lunning MA; Green MR
Blood Cancer J; 2015 Oct; 5(10):e361. PubMed ID: 26473533
[TBL] [Abstract][Full Text] [Related]
29. Flipping the cyclin D1 switch in mantle cell lymphoma.
Hasanali Z; Sharma K; Epner E
Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
[TBL] [Abstract][Full Text] [Related]
30. Mantle cell lymphoma with aberrant expression of CD10.
Zanetto U; Dong H; Huang Y; Zhang K; Narbaitz M; Sapia S; Kostopoulos I; Liu H; Du MQ; Bacon CM
Histopathology; 2008 Jul; 53(1):20-9. PubMed ID: 18518902
[TBL] [Abstract][Full Text] [Related]
31. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
Chakrabarty S; Varghese VK; Sahu P; Jayaram P; Shivakumar BM; Pai CG; Satyamoorthy K
Br J Cancer; 2017 Jun; 117(1):136-143. PubMed ID: 28524162
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
33. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.
Kanduri M; Sander B; Ntoufa S; Papakonstantinou N; Sutton LA; Stamatopoulos K; Kanduri C; Rosenquist R
Epigenetics; 2013 Dec; 8(12):1280-8. PubMed ID: 24107828
[TBL] [Abstract][Full Text] [Related]
34. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
35. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Camacho E; Hernández L; Hernández S; Tort F; Bellosillo B; Beà S; Bosch F; Montserrat E; Cardesa A; Fernández PL; Campo E
Blood; 2002 Jan; 99(1):238-44. PubMed ID: 11756177
[TBL] [Abstract][Full Text] [Related]
36. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.
Queirós AC; Beekman R; Vilarrasa-Blasi R; Duran-Ferrer M; Clot G; Merkel A; Raineri E; Russiñol N; Castellano G; Beà S; Navarro A; Kulis M; Verdaguer-Dot N; Jares P; Enjuanes A; Calasanz MJ; Bergmann A; Vater I; Salaverría I; van de Werken HJG; Wilson WH; Datta A; Flicek P; Royo R; Martens J; Giné E; Lopez-Guillermo A; Stunnenberg HG; Klapper W; Pott C; Heath S; Gut IG; Siebert R; Campo E; Martín-Subero JI
Cancer Cell; 2016 Nov; 30(5):806-821. PubMed ID: 27846393
[TBL] [Abstract][Full Text] [Related]
37. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
Izban KF; Alkan S; Singleton TP; Hsi ED
Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
[TBL] [Abstract][Full Text] [Related]
38. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
39. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
[TBL] [Abstract][Full Text] [Related]
40. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
Rosenwald A; Wright G; Wiestner A; Chan WC; Connors JM; Campo E; Gascoyne RD; Grogan TM; Muller-Hermelink HK; Smeland EB; Chiorazzi M; Giltnane JM; Hurt EM; Zhao H; Averett L; Henrickson S; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Montserrat E; Bosch F; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Fisher RI; Miller TP; LeBlanc M; Ott G; Kvaloy S; Holte H; Delabie J; Staudt LM
Cancer Cell; 2003 Feb; 3(2):185-97. PubMed ID: 12620412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
